^
    Back
    Association details:
    Biomarker:CD79B expression
    Cancer:T Cell Non-Hodgkin Lymphoma
    Drug:ARC-02 (Microtubule inhibitor, CD79b-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Blood
    Title:

    A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC

    Published date:
    11/15/2022
    Excerpt:
    ARC-02 was compared head-to-head to Polivy® in two different CD79b-expressing established tumor models in vivo (Granta-519 and Ramos). Single dose treatment of ARC-02 at very low payload doses induced effective and long-lasting anti-tumor responses with complete tumor eradication achieved at about half of the Polivy® payload dose in both NHL established tumor models.
    DOI:
    https://doi.org/10.1182/blood-2022-160056